Human transplacental passage of the retinoid fenretinide (4HPR) [2]

European Journal of Cancer

Volumn 34, Issue 3, 1998, Pages 428-429

  Formelli, F ^a   De Palo, G ^a   Costa, A ^b   Veronesi, U ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FENRETINIDE; ISOTRETINOIN; N (4 METHOXYPHENYL)RETINAMIDE; RETINOIC ACID; RETINOL; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG TRANSPORT; EMBRYO; FEMALE; HUMAN; LETTER; PLACENTA; PLACENTAL TRANSFER; PRIORITY JOURNAL; TERATOGENICITY;

EID: 0032007051     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10013-2     Document Type: Article

References (5)

1. 1. Kelloff GJ, Crowell JA, Boone CW, et al. Clinical development plan: N-(4-hydroxyphenyl)retinamide (4-HPR). J Cell Biochem 1994, 20, 176-196.
2. 2. Kenel MF, Krayer JH, Merz EA, Pritchard JF. Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits. Teratog Carcinog Mutag 1988, 8, 1-11.
3. 3. De Palo G, Veronesi U, Marubini E, et al. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. J Cell Biochem 1995, 22, 11-17.
4. 4. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokineties and effects on plasma retinol concentrations. J Clin Oncol 1993, 11, 2036-2042.
5. 5. Kraft JC, Nau H, Lammer E, Olney A. Embryonic retinoid concentrations after maternal intake of isotretinoin. N Engl J Med 1989, 321, 262.